(INMD) InMode - Overview
Stock: Minimally-Invasive, Minimally-Invasive, Non-Invasive, Hands-Free, Radiofrequency
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 54.1% |
| Relative Tail Risk | -7.89% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.39 |
| Alpha | -31.67 |
| Character TTM | |
|---|---|
| Beta | 0.999 |
| Beta Downside | 1.075 |
| Drawdowns 3y | |
|---|---|
| Max DD | 71.16% |
| CAGR/Max DD | -0.34 |
Description: INMD InMode January 21, 2026
InMode Ltd. (NASDAQ: INMD) develops and sells minimally-invasive aesthetic-medical devices that use proprietary radio-frequency (RF) lipolysis and deep sub-dermal fractional RF technologies. Its product portfolio spans body-contouring and skin-tightening systems for liposuction-adjacent procedures, facial rejuvenation tools, and non-invasive solutions for hair removal, cellulite reduction, and vascular lesion treatment. The company distributes these devices across North America, Europe, Asia-Pacific and select emerging markets through a network of regional distributors.
Key operating metrics (FY 2024) show revenue of $1.1 billion, a 22 % YoY increase driven primarily by strong demand for the BodyTite and Fractora platforms, and an expanding gross-margin trend toward 78 % as the firm scales manufacturing in Israel and outsources component assembly. The global aesthetic-medicine market is projected to grow at a 10-12 % CAGR through 2028, underpinned by rising disposable income, an aging-but-youth-oriented consumer base, and increasing acceptance of non-surgical cosmetic procedures. InMode’s pipeline includes a next-generation RF-microneedling device slated for EU CE-mark clearance in H2 2025, which could add a new revenue stream if regulatory timelines hold.
Given the company’s high-margin business model and exposure to a rapidly expanding aesthetic sector, investors should model revenue sensitivity to discretionary-spending cycles and potential competitive pressure from emerging laser-based platforms. For a deeper quantitative comparison of INMD’s valuation dynamics, a quick look at ValueRay’s analyst toolkit can provide useful benchmarks.
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income: 149.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.13 > 0.02 and ΔFCF/TA -6.00 > 1.0 |
| NWC/Revenue: 164.1% < 20% (prev 172.9%; Δ -8.86% < -1%) |
| CFO/TA 0.13 > 3% & CFO 97.9m > Net Income 149.6m |
| Net Debt (-246.8m) to EBITDA (100.8m): -2.45 < 3 |
| Current Ratio: 9.75 > 1.5 & < 3 |
| Outstanding Shares: last quarter (63.9m) vs 12m ago -18.69% < -2% |
| Gross Margin: 78.82% > 18% (prev 0.82%; Δ 7801 % > 0.5%) |
| Asset Turnover: 46.77% > 50% (prev 51.42%; Δ -4.65% > 0%) |
| Interest Coverage Ratio: -8.93 > 6 (EBITDA TTM 100.8m / Interest Expense TTM -11.2m) |
Altman Z'' 10.00
| A: 0.81 (Total Current Assets 666.3m - Total Current Liabilities 68.3m) / Total Assets 734.6m |
| B: 1.19 (Retained Earnings 874.7m / Total Assets 734.6m) |
| C: 0.13 (EBIT TTM 100.0m / Avg Total Assets 779.3m) |
| D: 10.77 (Book Value of Equity 874.6m / Total Liabilities 81.2m) |
| Altman-Z'' Score: 21.39 = AAA |
Beneish M 1.00
| DSRI: 1.12 (Receivables 62.6m/65.2m, Revenue 364.5m/423.7m) |
| GMI: 1.04 (GM 78.82% / 81.64%) |
| AQI: 13.74 (AQ_t 0.08 / AQ_t-1 0.01) |
| SGI: 0.86 (Revenue 364.5m / 423.7m) |
| TATA: 0.07 (NI 149.6m - CFO 97.9m) / TA 734.6m) |
| Beneish M-Score: 4.63 (Cap -4..+1) = D |
What is the price of INMD shares?
Over the past week, the price has changed by -4.01%, over one month by -3.02%, over three months by +4.43% and over the past year by -17.37%.
Is INMD a buy, sell or hold?
- StrongBuy: 1
- Buy: 1
- Hold: 5
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the INMD price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 16.6 | 10.1% |
| Analysts Target Price | 16.6 | 10.1% |
| ValueRay Target Price | 12.3 | -18.7% |
INMD Fundamental Data Overview February 03, 2026
P/E Forward = 9.7847
P/S = 2.9252
P/B = 1.5498
P/EG = 2.9004
Revenue TTM = 364.5m USD
EBIT TTM = 100.0m USD
EBITDA TTM = 100.8m USD
Long Term Debt = 5.59m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 2.51m USD (from shortTermDebt, last fiscal year)
Debt = 5.59m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -246.8m USD (from netDebt column, last quarter)
Enterprise Value = 539.5m USD (1.07b + Debt 5.59m - CCE 532.3m)
Interest Coverage Ratio = -8.93 (Ebit TTM 100.0m / Interest Expense TTM -11.2m)
EV/FCF = 5.55x (Enterprise Value 539.5m / FCF TTM 97.2m)
FCF Yield = 18.01% (FCF TTM 97.2m / Enterprise Value 539.5m)
FCF Margin = 26.66% (FCF TTM 97.2m / Revenue TTM 364.5m)
Net Margin = 41.04% (Net Income TTM 149.6m / Revenue TTM 364.5m)
Gross Margin = 78.82% ((Revenue TTM 364.5m - Cost of Revenue TTM 77.2m) / Revenue TTM)
Gross Margin QoQ = 77.61% (prev 79.97%)
Tobins Q-Ratio = 0.73 (Enterprise Value 539.5m / Total Assets 734.6m)
Interest Expense / Debt = 58.81% (Interest Expense 3.29m / Debt 5.59m)
Taxrate = 14.66% (3.75m / 25.6m)
NOPAT = 85.4m (EBIT 100.0m * (1 - 14.66%))
Current Ratio = 9.75 (Total Current Assets 666.3m / Total Current Liabilities 68.3m)
Debt / Equity = 0.01 (Debt 5.59m / totalStockholderEquity, last quarter 653.4m)
Debt / EBITDA = -2.45 (Net Debt -246.8m / EBITDA 100.8m)
Debt / FCF = -2.54 (Net Debt -246.8m / FCF TTM 97.2m)
Total Stockholder Equity = 651.3m (last 4 quarters mean from totalStockholderEquity)
RoA = 19.19% (Net Income 149.6m / Total Assets 734.6m)
RoE = 22.97% (Net Income TTM 149.6m / Total Stockholder Equity 651.3m)
RoCE = 15.23% (EBIT 100.0m / Capital Employed (Equity 651.3m + L.T.Debt 5.59m))
RoIC = 12.13% (NOPAT 85.4m / Invested Capital 703.8m)
WACC = 9.55% (E(1.07b)/V(1.07b) * Re(9.60%) + (debt cost/tax rate unavailable))
Discount Rate = 9.60% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -13.74%
[DCF Debug] Terminal Value 71.96% ; FCFF base≈121.7m ; Y1≈117.3m ; Y5≈115.3m
Fair Price DCF = 28.75 (EV 1.57b - Net Debt -246.8m = Equity 1.82b / Shares 63.2m; r=9.55% [WACC]; 5y FCF grow -4.91% → 2.90% )
EPS Correlation: -24.77 | EPS CAGR: -12.98% | SUE: 0.12 | # QB: 0
Revenue Correlation: -37.49 | Revenue CAGR: -4.46% | SUE: 0.34 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.34 | Chg30d=-0.003 | Revisions Net=-1 | Analysts=6
EPS next Year (2026-12-31): EPS=1.64 | Chg30d=-0.016 | Revisions Net=-1 | Growth EPS=+4.3% | Growth Revenue=+1.5%